Purpose: Evidence indicates that long noncoding RNAs (lncRNA) possess important roles in various cellular processes and that dysregulation of lncRNAs promotes tumor progression. However, the expression patterns and biological functions of many specific lncRNAs in breast cancer remain to be determined. Methods: Quantitative real-time polymerase chain reaction was performed to detect Linc00460, miR-489-5p and FGF7 expression. Protein levels were determined using Western blot. MTT and colony formation assay were used to measure cell proliferation. Transwell assays were conducted to determine cell migration and invasion. Luciferase reporter assays were carried out to assess the interaction between miR-489-5p and Linc00460 or FGF7. Biotin pull-down assay was used to detect the direct interaction between miR-489-5p and Linc00460. In vivo experiments were performed to measure tumor formation and lung metastasis. Results: We demonstrated that lncRNA Linc00460 was upregulated in breast cancer, and its expression level was positively associated with lymphatic metastasis and poor overall survival. Forced expression of Linc00460 increased, whereas Linc00460 silencing decreased, breast cancer cell viability, migration and invasion both in vitro and in vivo. Linc00460 was identified as a direct target of miR-489-5p, which further targeted FGF7 and exerted oncogenic functions in breast cancer. Mechanistically, Linc00460 served as a competing endogenous RNA of FGF-7 mRNA by sponging miR-489-5p, resulting in upregulated FGF7 expression and AKT activity. Notably, forced expression of miR-489-5p abrogated Linc00460-mediated oncogenic behavior and activation of the FGF7-AKT pathway in breast cancer cells. Conclusion: We have demonstrated that Linc00460 promotes breast cancer progression partly through the miR-489-5p/FGF7/AKT axis.
Introduction
Breast cancer is the most prevalent female malignancy. 1 Despite significant progress in the diagnosis and treatment of breast cancer, the mortality of patients with advanced breast cancer remains high, being mainly attributed to frequent metastasis and recurrence. 2, 3 Long noncoding RNAs (lncRNAs) are defined as transcribed RNA molecules of more than 200 nucleotides with no protein-coding capacity and account for the majority of the transcribed genome. 4 LncRNAs have been increasingly recognized the functional role of Linc00460 in breast cancer.
In the present study, we observed the increased expression of Linc00460 in breast cancer compared to the benign breast tissues. Moreover, Linc00460 expression in the breast cancer cohort was associated with lymph node metastasis and worse survival outcome. Linc00460 depletion decreased breast cancer cell proliferation, migration and invasion, and inhibited tumor growth and lung metastasis in vivo. Mechanistically, our study suggests that Linc00460 sponges endogenous miRNA-489-5p to activate FGF7-AKT signaling, thereby promoting breast cancer progression.
Materials and methods

Breast cancer specimens and cell lines
Forty-two breast cancer tissues and 15 benign mammary tissues were collected from patients who underwent surgery at the First Affiliated Hospital of Anhui Medical University (Hefei, Anhui, People's Republic of China) between 2009 and 2010. Specimens were transported in liquid nitrogen and stored at -80°C until used. The inclusion criteria were as follows: patients had no history of prior therapy with anticancer drugs or radiotherapy; clinical information of each patient including age, tumor size, tumor stage and lymphatic metastasis was available and written informed consent was obtained from all patients. The study protocol regarding the use of clinical samples was reviewed and approved by the Biomedical Ethics Committee of Anhui Medical University and conducted in accordance with the Declaration of Helsinki. Data from GSE20711 and GSE6532 in the GEO database were extracted to analyze the expression patterns of Linc00460 and FGF7 in the breast cancer tissues. Breast cancer cell lines (MCF-7, BT-474, MDA-MB-231 and BT-549) and a mammary epithelial cell line (MCF-10A) used in this study were purchased from the American Type Culture Collection (Rockville, MD, USA). HMEC-hTERT cells were a gift of Prof. William Hahn, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America. SUM159 and SUM149 cells were obtained from Asterand. 18 Cell lines used in this study have been authenticated. MCF-7 and BT-474 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco) at 37°C with 5% CO 2 . BT-549 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 0.01 mg/mL human recombinant insulin (Sigma) at 37°C with 5% CO 2 . MDA-MB-231 cells were cultured in Leibovitz's15 medium supplemented with 10% fetal bovine serum at 37°C in the absence of CO 2 . SUM159 and SUM149 cells were cultured in Ham F-12 (Invitrogen) supplemented with 5% fetal bovine serum, 5 µg/mL insulin and 1 µg/mL hydrocortisone (Sigma) at 37°C with 5% CO 2. Cell culture medium for HMEC-TERT and MCF-10A cells was prepared as previously described. 19 
RNA extraction and qRT-PCR analysis
Total RNA was isolated from cells and clinical specimens using Trizol (Invitrogen, Carlsbad, CA) and converted to cDNA using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific Bio) following the manufacturer's instructions. The resulting cDNA samples were analyzed by qPCR prepared using SYBR Premix Ex Taq Kit (Takara) and run on Stratagene Mx3000P (Agilent Technology). The expression levels of mRNAs and miRNAs were normalized to the expression level of GAPDH and U6 snRNA, respectively. The sequences of primers used are listed in Table S1 .
Lentivirus production and stable cell line construction
The full-length Linc00460 DNA fragment was cloned and inserted into pSin vector (pSin) according to the manufacturer's instructions. shRNAs targeting Linc00460 were synthesized and cloned into pLKO.1 vector. All primers and shRNA sequences are listed in Table S1 . Lentivirus production and transduction were performed as previously 
MTT assays
Cells were seeded into 96-well plates at 1,000 cells per well 48 hrs after transfection or the indicated treatments. Cells were cultured for 5 days and cell viability was determined using the MTT reagent (Promega). Absorbance at 570 nm was measured after 2 hrs of incubation with the MTT reagent.
Colony formation assays
Cells were seeded into 6-well plates at 1,000 cells per well 48 hrs after transfection or the indicated treatments. After 10 days of culture, cells were washed with PBS, fixed with 10% formalin and stained with 0.5% crystal violet (Sigma). Representative images were used for the counting of respective colony numbers in each well.
Migration and invasion assays
Cells were seeded into the upper chamber of a 24-well transwell insert (8-μm pores, BD Biosciences, San Jose, CA) at 10 5 cells per well 48 hrs after transfection or the indicated treatments. Complete medium was added into the lower chamber. After 24-48 hrs, the remaining cells in the upper chamber were gently wiped off with a cotton swab. Cells migrated through the pores in the membrane to the lower surface of the chamber were fixed with 90% ethyl alcohol for half an hour and stained with 0.1% crystal violet. Images of the migrated cells were taken in three randomly chosen fields and the number of cells in each field was counted. The protocol of invasion assay is similar to migration except that the upper chambers were precoated with Matrigel (BD Biosciences) which was diluted by the FBS free medium.
Transfection and luciferase reporter assays
Full-length Linc00460 and 3'UTR of FGF7 were amplified and cloned separately into psiCHECK-2 vector. Linc00460 with mutated miR-489-5p-binding site (Linc00460-mut) was obtained by using specific primers as stated in Table S1 . 5×10 4 MDA-MB-231 or MCF-7 cells were seeded into each well of 24-well plates 24 hrs before transfection. miR-489-5p mimics, miR-489-5p inhibitor or the respective scrambled oligonucleotides control was co-transfected with 0.1 µg of empty psiCHECK-2 vector control or psiCHECK-2 vectors containing Linc00460, Linc00460-mut or FGF7 3'UTR into the cells using Lipofectamine 2000 (Invitrogen). Cells were harvested and lysed 48 hrs after transfection, the luciferase activities were determined by Dual-Luciferase ® Reporter
Assay System (Promega).
Biotin pull-down assay
The detailed protocol was described previously. 22 Briefly, sense or antisense biotin-labeled DNA oligomers targeting Linc00460 were incubated with lysates from MCF-7 cells. Streptavidin-coupled agarose beads (Invitrogen) were used to enrich the Linc00460 complex 1 hr after incubation. All steps were performed in RNase-free environment. Sequences of probes against Linc00460 are listed in Table S1 .
Anti-AGO2 RNA immunoprecipitation
Anti-AGO2 RNA immunoprecipitation was performed as previously described. 23 Briefly, breast cancer cells were lysed and the extract was incubated with anti-AGO2 antibody or anti-IgG (Santa Cruz, CA, USA). Protein G agarose beads (Invitrogen) was used to adhere to the immunoprecipitation product. Beads were washed and subjected to RNA extraction. Purified RNA was analyzed by qRT-PCR.
Protein extraction and Western blot
Total protein from cells was extracted by modified RIPA lysis buffer. Western blot was performed as previously described. 24 Protein expression was analyzed by ImageQuant LAS4000 (GE Health). All antibodies used are listed in Table S2 .
Xenograft and histological analyses
The protocol for animal experiments was approved by the Institutional Animal Care and Use Committee and followed the guideline of experimental animal welfare of the Laboratory Animal Ethical Committee at University of Science and Technology of China (USTCACUC1601015). Estradiol pellet (0.18 mg) was subcutaneously implanted into the dorsal skin of 4-week-old nude mice 1 week prior to injection of the MCF-7 cells. For the xenograft study, 5×10 6 MCF-7 control cells, or MCF-7 cells stably transfected with Linc00460, were mixed 1:1 with Matrigel (BD Biosciences) and injected into the second mammary fat pad of the nude mice (N=6). Tumor growth was determined by measuring the length (L) and width (W). Figure 1A ). Next, we analyzed Linc00460 level in 42 breast cancer and 15 normal breast specimens. The expression levels of Linc00460 were found to be significantly elevated in breast cancer compared to the normal breast tissue ( Figure 1B ). As indicated in Figure 1C) . Consistently, increased expression of Linc00460 was observed in breast cancer compared to normal breast tissues in the TCGA BRCA cohorts with 1102 breast cancer tissues and 113 normal breast tissues ( Figure 1D ). A positive correlation between Linc00460 expression and lymphatic metastasis was also observed in the GSE20711 dataset ( Figure 1E ). Furthermore, patients with a higher expression level of Linc00460 exhibited a shorter overall survival rate.
( Figure 1F ). In addition, the prognostic value of Linc00460 was evaluated by univariate and multivariate Cox proportional hazards regression analyses. It was observed that Linc00460 was an independent prognostic factor for worse overall survival (HR =4.763, 95% CI: 1.135-19.985, P=0.033; Table 2 ). Collectively, these data suggest that Linc00460 is upregulated in breast cancer and is associated with a poor survival outcome.
Linc00460 promotes the oncogenicity of breast cancer cells in vitro and in vivo sections revealed significant local invasion in tumors derived from MCF-7-Linc00460 cells, but not in tumors derived from MCF-7-vector cells ( Figure 2M ). To further assess the effect of Linc00460 on breast cancer metastasis, MDA-MB-231 cells transfected with either shRNA targeting Linc00460 or empty vector, were injected via the tail vein of 6-week-old nude mice. Depletion of Linc00460 expression produced a significant reduction in the number and size of lung micrometastases derived from metastatic MDA-MB-231 cells ( Figure 2N ). Furthermore, while all mice injected with MDA-MB-231-vector cells exhibited lung metastases (100%), a markedly lower frequency of lung metastases (only 25% and 12.5%) was observed in mice injected with MDA-MB-231-shLinc00460 cells ( Figure 2O ).
Linc00460 sponges miR-489-5p in breast cancer cells
It has been reported that Linc00460 is abundantly expressed in the cytoplasm, suggestive of the possibility that Linc00460 acts as competitive endogenous RNA (ceRNA) or sponges of miRNAs in breast cancer. 15, 16 miRNAs may act as regulatory adaptors, through which lncRNAs, pseudogenes and messenger RNAs form regulatory crosstalk networks. 26 Therefore, we hypothesized that Linc00460 may be a target of tumor suppressive miRNAs. We therefore searched the list of miRNAs predicted to target Linc00460 using miRcode (http://www. mircode.org/mircode/) and RNAhybrid （https://bibiserv. cebitec.uni-bielefeld.de/rnahybrid）. Eight of the identified predicted miRNAs have been reported to be tumor suppressors, of which three were significantly upregulated as a result of Linc00460 repression (data not shown) and only one of the three (miR-489-5p) was downregulated with forced expression of Linc00460 in breast cancer cells, suggestive that Linc00460 may be a target of miR-489-5p ( Figure 3A-C) . A potential miR-489-5p-binding site was also predicted on Linc00460 ( Figure 3D ). To verify the functionality of this binding site, Linc00460 with wild type or mutant miR-489-5p-binding sites were cloned into dual luciferase reporter vector (psiCHECK-2) and co-transfected with miR-489-5p or scrambled oligonucleotides into MCF-7 and MDA-MB-231 cells. Forced expression of miR-489-5p significantly decreased wild-type Linc00460-driven luciferase reporter activity but not that of the mutant Linc00460-driven luciferase reporter activity in both cell lines ( Figure 3E ). Furthermore, miR-489-5p, together with Linc00460, were enriched in the pull-down fraction of MCF-7 cells using biotin-conjugated probes against Linc00460 ( Figure 3F ). Concordantly, we observed a negative correlation between Linc00460 and miR-489-5p expression in breast cancer tissues by Pearson correlation analysis ( Figure 3G ). Additionally, expression levels of miR-489-5p were significantly lower in breast cancer compared to normal breast tissues ( Figure 3H ), further confirming that miR-489-5p functions as a tumor suppressor.
MiR-489-5p acts as a tumor suppressor in breast cancer
To verify the tumor suppressive role of miR-489-5p in breast cancer, MCF-7 and MDA-MB-231 cells were transfected with miR-489-5p mimics, single-strand miR-489-5p inhibitor or the respective scrambled oligonucleotides as the negative control ( Figure 4A and B) and cell functions determined. MTT assays suggested that the forced expression of miR-489-5p decreased, while inhibition of miR-489-5p increased cell viability ( Figure 4C and D) . A similar result was observed in the colony formation assay ( Figure 4E and F) . Moreover, forced expression of miR-489-5p suppressed, while inhibition of miR-489-5p promoted the migration and invasion of MCF-7 and MDA-MB-231 cells in transwell assays ( Figure 4G -J).
Linc00460 competes with FGF7 for binding of miR-489-5p
We further determined the functional targets of miR-489-5p in breast cancer. FGF7 was predicted to contain a conserved miR-489-5p-binding site using TargetScan (http://www.targetscan.org/) ( Figure 5A ). 27 To verify that miR-489-5p targeted FGF7 mRNA, the 3'UTR of FGF7 was cloned into the psi-CHECK2 luciferase reporter plasmid and co-transfected with miR-489-5p mimics, miR-489-5p inhibitor or scrambled oligonucleotides into MCF-7 or MDA-MB-231 cells. Forced expression of miR-489-5p inhibited, while miR-489-5p antagonism increased FGF7 3'UTR-driven luciferase reporter activity in both MCF-7 and MDA-MB -231 cells ( Figure 5B and 5C). We also examined whether miR-489-5p directly regulated FGF7 expression. Forced expression of miR-489-5p decreased, whereas miR-489-5p inhibition increased the mRNA and protein levels of FGF7 in MCF-7 and MDA-MB-231 cells ( Figure 5D and E). As both Linc00460 and FGF7 are direct miR-489-5p targets, we next determined whether they competed for binding to miR-489-5p. Forced expression of Linc00460 increased FGF7 expression, whereas Linc00460 depletion decreased FGF7 expression in MCF-7 cells or MDA-MB-231 cells compared to control (Figure 5F -I). Elevated FGF7 expression has been reported to promote AKT signaling 28 , and we therefore examined AKT activity (phosphorylation) in these cells. We observed that the level of phosphorylated AKT was increased in MCF7 and MDA-MB-231 cells with forced expression of Linc00460 ( Figure 5H and I). In contrast, phosphorylation of AKT was reduced, consistent with a decrease in FGF7 expression in MCF7 and MDA-MB-231 cells, upon Linc00460 depletion ( Figure 5H and I) . Additionally, analysis of the expression levels of Linc00460 and FGF7 from the GSE6532 dataset showed a significant positive correlation by Pearson correlation analysis ( Figure 5J ). We finally performed an anti-AGO2 RNA immunoprecipitation assay and observed Linc00460 overexpression reduced the enrichment of FGF7 mRNA on RISC by miR-489-5p in MCF7 and MDA-MB-231 cells ( Figure 5K-P) . Collectively, miR-489-5p inhibits FGF7-AKT signaling, in a manner that is inversely dependent on Linc00460 expression.
Linc00460 promotes oncogenicity through the miR-489-5p/FGF7/AKT axis
The FGF7-AKT axis has been reported to promote breast cancer progression. 29, 30, 31 We therefore sought to determine whether the miR-489-5p/FGF-7/AKT axis mediated linc00460-mediated oncogenic behaviors in breast cancer cells. miR-489-5p mimics or scrambled oligonucleotides were transfected into MCF-7 cells to rescue Linc00460 overexpression reduced expression of miR-489-5p. As expected, forced expression of miR-489-5p abolished the growth, migration and invasion advantage conferred by Linc00460 overexpression in MCF-7 cells, as determined by MTT, colony formation and transwell assays ( Figure 6A-D) . Conversely, miR-489-5p inhibition rescued diminished growth, migration and invasion consequent to Linc00460 depletion in MDA-MB-231 cells ( Figure 6E-H) . Consistently, forced expression of miR-489-5p attenuated the Linc00460-mediated increase in FGF7 expression and AKT phosphorylation in MCF-7 cells ( Figure 6I and J). In contrast, miR-489-5p inhibition rescued the Linc00460 depletion-mediated decrease in FGF7 expression and AKT phosphorylation in MDA-MB-231 cells ( Figure 6I and K). We further determined if FGF7 and its downstream signaling mediated the oncogenic functions of Linc00460.
Linc00460 overexpressing breast cancer cell lines were transfected with FGF7 siRNAs or negative control. FGF7 depletion suppressed the Linc00460-mediated increase in p-AKT levels to levels similar to that of vector control cells ( Figure 7A-C) . Functionally, MTT and colony formation assays revealed that FGF7 silencing attenuated Linc00460-induced proliferation and/or survival of breast cancer cells to levels similar to that of vector control cells (Figure 7D-G) . 
pSin-vec+si-NC pSin-vec+si-FGF7 pSin-460oe+si-NC pSin-460oe+si-FGF7 Furthermore, transwell assays showed that FGF7 depletion abrogated Linc00460-enhanced migratory and invasive capacities of breast cancer cells to levels similar to that of vector control cells ( Figure 7H-K) . Thus, FGF7 and its downstream AKT signaling mediate the oncogenic role of Linc00460.
Discussion
In this study, we investigated the expression pattern and clinical relevance of Linc00460 in breast cancer. We observed that Linc00460 was frequently upregulated in breast cancer. Forced expression of Linc00460 promoted viability, migration and invasion of breast cancer cells both in vitro and in vivo. Mechanistically, Linc00460 promoted breast cancer progression by sponging miR-489-5p and functioning as a competing endogenous RNA to FGF7 mRNA, consequently elevating FGF7 expression and enhancing its downstream AKT signaling. 28 Recent studies have reported that the expression of Linc00460 is deregulated in renal cell carcinoma and head and neck squamous cell carcinoma. 13 In addition, Linc00460 has also been reported to contribute to the development and progression of esophageal cancer and nasopharyngeal carcinoma. 15, 16 However, the underlying mechanism(s) by which Linc00460 promotes oncogenicity is not well delineated. We herein demonstrated that Linc00460 is a direct target of miR-489-5p. miR-489-5p has been reported to impair breast cancer proliferation and invasion by targeting the GSE1 coiled-coil protein. 32 Interestingly, miR-489-3p, which originates from the same precursor, has been widely demonstrated to be a tumor suppressor, with functions in colorectal cancer, bladder cancer and osteosarcoma amongst other cancers. [33] [34] [35] miR-489-3p has been reported to target histone deacetylase 7 (HDAC7) to suppress tumor growth and invasion in colon cancer. 33 It has also been reported that the oncogenic KRAS/NF-kappaB/YY1 axis repressed miR-489-3p expression, leading to pancreatic cancer metastasis. 36 In this study, we further investigated the functionality of miR-489-5p. In contrast to Linc00460, miR-489-5p was observed to be dramatically downregulated in breast cancer as compared to benign breast tissues. Functionally, we observed that miR-489-5p significantly inhibited the proliferation, migration and invasion of breast cancer cells, acting as a potent tumor suppressor.
Herein, FGF7 was identified as a target of miR-489-5p, competing with Linc00460 for miR-489-5p binding. FGF7 is a mesenchyme-specific heparin-binding growth factor that binds FGF receptor 2 (FGFR2) to regulate numerous cellular processes. 37, 38 Signaling pathways activated downstream of FGF7/FGFR2 include RAS-mitogenactivated protein kinase, Phospholipase C-γ, phosphoinositide3-kinase and Janus kinase/signal transducer and activator of transcription. 28, 39, 40 Activation of FGF7/ FGFR2 signaling has been reported to contribute to development and progression of gastric cancer, prostate cancer, lung adenocarcinoma and breast cancer. 37, [41] [42] [43] In the current study, we have demonstrated that increased Linc00460 expression inhibits miR-489-5p-mediated downregulation of FGF7 expression and is accompanied by consequent activation of FGF7-AKT pathway in breast cancer cells, revealing a novel cellular mechanism regulating the FGF7 pathway. Linc00460 expression has previously been reported to be regulated by several well-known cancer-related transcription factors such as MYC, FOS, CTCF and JUN via bioinformatics prediction. 17 Together with the prediction from rVista 2.0 (https://rvista.dcode.org/ instr_rVISTA.html), we studied the effect of MYC, SP1, FOS transcription factors on the modulation of Linc00460 expression. However, we did not observe a significant change in the expression level of Linc00460 upon the depletion of these transcription factors. Therefore, the mechanism responsible for the upregulation of Linc00460 in breast cancer remains to be further investigated.
Conclusion
We demonstrated that Linc00460 was increased in expression in breast cancer and that the Linc00460/ miR-489-5p/FGF7/AKT axis promoted proliferation, migration and invasion in breast cancer. A higher expression level of Linc00460 was prognostic for a shorter overall survival rate in breast cancer patients. Therefore, Linc00460 is a potential novel diagnostic biomarker for breast cancer prognosis. 
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